Elon Musk wants to use the Neuralink technology to help people lose weight, but experts are doubtful.

 Previously, Musk stated that BCIs may be used to treat severe depression, morbid obesity, and sleep issues.

Elon Musk's idea to use his brain-computer interface (BCI) startup, Neuralink, for weight loss has generated safety worries among specialists.

Musk previously stated that BCIs might be used to treat conditions such as severe depression, morbid obesity, and sleep disorders.

Nonetheless, pundits contend that the obtrusive idea of BCI techniques, implying mind a medical procedure and possible dangers, makes them less good contrasted with elective weight reduction mediations.

While BCIs like Neuralink have shown outcome in supporting people with loss of motion, the possibility of involving them for weight control raises moral and security contemplations.

The US Government Responsibility Office features careful dangers, for example, contamination and dismissal related with embedded BCIs.

Conversely, another class of medications known as "glucagon-like peptide 1 agonists" (GLP-1s) presents a more secure and more powerful choice for weight reduction.

GLP-1s, at first intended for diabetes treatment, have shown hunger stifling impacts by easing back the development of food through the stomach related framework.

The US Food and Medication Organization as of late endorsed Eli Lilly's GLP-1 medication, Zepbound, explicitly for stoutness treatment.

The wellbeing and viability of GLP-1 medications, directed through infusions, have been insisted through huge scope preliminaries.

Significantly, these medications are suggested related to a diminished calorie diet and expanded actual work.

Specialists underline that GLP-1 medications offer a sub-atomic way to deal with hunger control with less dangers contrasted with obtrusive BCI methodology.

Pundits highlight the potential for misuse and unfriendly impacts related with hunger-controlling intercessions, whether through inserts or medications.

Nonetheless, clinical experts contend that appropriate screening can recognize people in danger of dietary problems, limiting expected hurt.

The authentic point of reference of the Minnesota Starvation Examination represents the complicated connection between food limitation and mental impacts, underlining the significance of wary ways to deal with weight reduction mediations.

All in all, the accessibility of protected and compelling GLP-1 medications recommends a more reasonable way for weight reduction mediations than obtrusive BCIs.

Specialists ask careful investigation of elective choices, including way of life changes and drug mediations, prior to considering trial cerebrum chip systems for conditions with laid out, more secure other options.